Targeting interleukin-4 to the arthritic joint

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Anti-inflammatory cytokines show promise for rheumatoid arthritis (RA) treatment.
• Current limitations include rapid clearance and systemic toxicity of cytokine therapeutics.
• Interleukin-4 (IL4) is a cytokine with therapeutic potential for RA.

Purpose of the Study:

• To enhance the pharmacokinetic properties of IL4 for RA therapy.
• To engineer a site-specific IL4 conjugate using genetic code expansion.
• To evaluate the bioactivity, pharmacokinetics, and joint accumulation of the engineered IL4.

Main Methods:

• Incorporation of an unnatural amino acid into murine IL4 via genetic code expansion.
• Site-specific conjugation of PEG-folate (targeting) or PEG (control) to the engineered IL4.
• Assessment of macrophage polarization, terminal half-life in mice, and joint accumulation using fluorescence imaging in an antigen-induced arthritis (AIA) model.

Main Results:

• Both IL4 conjugates retained bioactivity and induced M2-like macrophage polarization.
• PEGylated IL4 conjugates exhibited a significantly increased terminal half-life (approx. 4 hours) compared to unPEGylated IL4 (0.76 hours).
• Conjugates successfully accumulated in arthritic joints of the AIA mouse model, confirmed by non-invasive fluorescence imaging.

Conclusions:

• Engineered IL4 conjugates demonstrate improved pharmacokinetic profiles and targeted delivery to inflamed joints.
• The modular conjugation chemistry allows for optimization of half-life and targeting moieties.
• These findings support further investigation of IL4 conjugates for rheumatoid arthritis treatment.